SGLT2 Inhibitors 2016: Year-End News Roundup
SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.
We present a review of developments in SGLT2 inhibitors for the year 2016 â from the EMPA-REG OUTCOMES trial to successful dual therapy treatments to FDA advisories and safety guidelines.See the slide legends for links to the article summaries.
Recent Videos
Related Content
